Search

everythinglearnresearchcommunity

for

Search:↓

UVB exposure in human skin causes macrophages to produce more IL-10 and less IL-12, leading to immunosuppression.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.

Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

Blocking certain proteins on immune cells may help treat alopecia areata.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.

Immunoadsorption successfully treated a man's resistant polymyositis.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

Combined therapy reduces inflammation and restores immune balance in alopecia areata patients.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

Enhancing glycolysis in mesenchymal stromal/stem cells boosts their immune functions and therapy potential.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Sequential immunotherapy can effectively treat alopecia areata by managing inflammation and promoting hair regrowth.

The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.

Age-related immune changes significantly affect disease development in other systems.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

Autoimmune diseases need combined therapy of tolerance induction and immunosuppression.

The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.

Targeted immune modulation can help achieve stable remission in alopecia areata.

Regulatory T cells and mesenchymal stem cells work together to prevent immune system overreactions and tissue damage.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

Low-output laser irradiation can stimulate or inhibit biological processes depending on the dose.